REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

Mon 18:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb5059Ga&default-theme=true

RNS Number : 5059G  Avacta Group PLC  28 April 2025

 

 

 

 

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

LONDON AND PHILADELPHIA - April 28, 2025, Avacta Therapeutics (AIM: AVCT,
'the Company'), a life sciences company developing next generation peptide
drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the
tumor, today makes the following notification pursuant to Schedule Six of the
AIM Rules for Companies regarding its existing block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 October 2024          27 April 2025
 Balance of unallotted securities under scheme(s) from previous return:              275,380
 Plus:   The amount by which the block scheme(s) has been increased since            nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 47,000
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         228,380

 

 Name of applicant:                                                                     Avacta Group plc
 Name of scheme:                                                                        LTIP/ESOS scheme
 Period of return:            From:                                                     28 October 2024            27 April 2025
 Balance of unallotted securities under scheme(s):                                      5,913,257
 Plus:   The amount by which the block scheme(s) has been increased since               nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                    4,366,882
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:            1,546,375

  Name of contact:                                         Brian Hahn, Company Secretary
 Telephone number of contact:                              + 44 (0) 1904 217070

 

Ends-

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)

 James Steel / Chris Golden                                 www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)

 Emma Earl / Will Goode / Mark Rogers                       www.panmureliberum.com

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPPUGACUPAGQR